NEW YORK (GenomeWeb) – GenePeeks announced today that it signed an agreement under which its preconception screening test will be distributed in Greece and Cyprus by primary healthcare services provider Bioiatriki.
GenePeeks' recently launched test uses potential parents' variant information to computationally create virtual genomes of potential children they might conceive. Based on detected mutations in these hypothetical genomes, the company generates a score that predicts gene function and associated disease risk for more than 1,100 genetic diseases.
Specific terms of the deal with Bioiatriki, which operates 29 diagnostic centers in Greece and Cyrus, were not disclosed.
"With this agreement, we are continuing our international expansion and increasing access to our advanced analytics platform," GenePeeks Cofounder and CEO Anne Morriss said in a statement.
In recent months, GenePeeks has formed several new partnerships with fertility organizations for its screening test and signed a distribution deal covering the Middle East and Africa with Alliance Global Group.